BIAF: financial statements from SEC — TradeAlmanac

BIAF

bioAffinity Technologies, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024
Revenue	1m	1m	1m	2m	2m
Research and development	349,707	330,589	311,372	367,386	274,497
Selling, general and administrative	3m	2m	2m	2m	2m
Operating expenses	5m	4m	4m	4m	4m
Operating income	−4m	−2m	−3m	−3m	−2m
Pre-tax income	−4m	−5m	−4m	−3m	−2m
Income tax	—	3,182	28,984	8,695	2,559
Net income	−4m	−5m	−4m	−3m	−2m
Earnings per share	−0.81	−4.74	−0.17	−0.16	−4.84
Earnings per share, diluted	−0.81	−4.74	−0.17	−0.16	−4.84
Weighted average shares	4m	1m	24m	16m	412,936
Weighted average shares, diluted	4m	1m	24m	16m	412,936

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Apr 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024
Cash and equivalents	3m	6m	8m	802,835	—	444,706	1m	756,580
Inventory	77,887	53,548

Cash flow

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024
Operating cash flow	−3m	—	—	−2m	—
Depreciation and amortisation	114,518	113,360	113,229	154,588	151,298
Share-based compensation

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)